1

Brain Tumor 2017

Brain Tumor Meeting 2017

May 18 - 19, 2017Campus Berlin-Buch

Max Delbrck Communications Center (MDC.C)Robert-Rssle-Str. 10

D-13125 Berlin, Germany

Program and Abstracts(Plenaries, Orals and Posters)

This meeting is an activity of

Brain Tumor 2017

2

Campus Berlin-Buch

C31.1- MDHC31 - MDH - Max-Delbrck-HausC84 - Hermann-von-Helmholtz-HausC83 - MDC.CC81 - FMPC71 - Tier- und LaborgebudeD85 - Arnold-Graffi-HausD82 - Karl-Lohmann-HausD80 - Otto-Warburg-HausD79 - Erwin-Negelein-HausD72 - Haus 72D23 - Eckert & Ziegler AGD16 - Bebig GmbH

A9 - PfrtnerA8 - TorhausA15 - Charles River Deutschland GmbHA14 - MensaA13 - Infocenter, Glsernes LaborA10 - BibliothekB64 - epo GmbHB63 - TierhausB61 - Salvadore-Luria-HausB55 - OCVH - Oskar-und-Ccile-Vogt-HausB54 - Hans-Gummel-GstehausB46 - Robert-Rssle-KlinikC27 - Walter-Friedrich-HausC87 - Timofeff-Ressovsky-Haus

3

Brain Tumor 2017

Table of Contents

Acknowledgement 4

Scientific Program 5

List of Plenary Lectures 7

Abstracts of Plenary Lectures 8

List of Oral Presentations selected from Abstracts 10

Abstracts of Oral Presentations 11

List of Poster Presentations 15

Abstracts of Poster Presentations 25

Address List 57

Scientific Committee

Christoph Harms(Charit - Universittsmedizin Berlin, Centrum fr Schlaganfallforschung Berlin)

Frank Heppner(Charit - Universittsmedizin Berlin, Institut fr Neuropathologie)

Helmut Kettenmann (Max-Delbrck-Centrum fr Molekulare Medizin, Zellulre Neurowissenschaften, Chair)

Jrgen Kiwit (Helios Klinikum Buch, Klinik fr Neurochirurgie)

Michael Synowitz(Universittsklinikum Schleswig-Holstein, Klinik fr Neurochirurgie, Co-chair)

Peter Vajkoczy(Charit - Campus Virchow-Klinikum, Klinik und Poliklinik fr Neurochirurgie)

Susanne Wolf(Max-Delbrck-Centrum fr Molekulare Medizin, Zellulre Neurowissenschaften)

Brain Tumor 2017

4

Acknowledgement

Cyagen Biosciences GmbH, Neu-Isenburg

Deutsche Forschungsgemeinschaft Bonn

3di GmbH, Jena

Einstein Center for Neuroscience Berlin

Helios Kliniken, Berlin-Buch

Max Delbrck Center for Molecular Medicine (MDC) in der

Helmholtz-Gemeinschaft, Berlin - Buch

NeuroCure Cluster of Excellence, Berlin

World Precision Instruments, Berlin

We gratefully acknowledge the financial support of the following partners:

5

Brain Tumor 2017

Scientific Program

Thursday, May 18, 2017

14.00 -14.05 Welcome Address: Helmut Kettenmann

14.05 - 15.25 Session I Chair: Jrgen Kiwit14.05 - 14.45 Plenary Lecture I Eric Charles Holland (Seattle, USA) Gliomas: Big human data and mouse models

14.45 - 15.05 Oral Presentation I Roberto Fiorelli (Phoenix, USA) Molecular and cyto-architectonic reshaping of the human svz during glioma invasion 15.05 - 15.25 Oral Presentation II Dinorah Friedmann-Morvinski (Tel Aviv, Israel) Functional characterization of oncogenic-induced cell pasticity in glioblastoma

15.25 - 16.00 Poster Session and Coffee Break

16.00 - 17.20 Session II Chair: Susanne Wolf16.00 - 16.40 Plenary Lecture II Cameron W. Brennan (New York, USA) Molecularheterogeneityandinstabilityofdiffusegliomas:modelsandclinicalpractice

16.40 - 17.00 Oral Presentation III Ccile Maire (Hamburg, Germany) Optical barcoding: A new technique to analyze tumor heterogeneity

17.00 - 17.20 Oral Presentation IV Paolo Malatesta (Genoa, Italy) Immunoescape during glioma progression

17.20 - 17.50 Poster Session and Coffee Break

17.50 - 19.10 Session III Chair: Peter Vajkoczy17.50 - 18.30 Plenary Lecture III Frank Winkler (Heidelberg, Germany) News from tumor microtubes in gliomas

18.30 - 18.50 Oral Presentation V Pooran Singh Dewari (Edinburgh, UK) AnefficientandscalableCRISPR/Cas9pipelineforepitopetagginginneuralandgliomastemcells

18.50 - 19.10 Oral Presentation VI Roland Klin (Mnchen, Germany) Newlyidentifiedpericyte-progenitorcellspromoteGBM-angiogenesis

19.15 - 20.00 Bus Transfer to the Berlin Museum of Medical History / Charit

20.00 Reception at the Berlin Museum of Medical History / Charit

Brain Tumor 2017

6

Friday, May 19, 2017

9.00 - 10.20 Session IV Chair: Christoph Harms9.00 - 9.40 Plenary Lecture IV Colin Watts (Cambridge, UK) Surgical strategies to interrogate the genomics of glioblastoma

9.40 - 10.00 Oral Presentation VII Hrvoje Miletic (Bergen, Norway) Long-term prodrug administration improves lentiviral vector mediated suicide gene therapy of glioblastoma

10.00 - 10.20 Oral Presentation VIII Julia Neumann (Hamburg, Germany) Activation of shh-and wnt-signaling in neural progenitors drives formation of embryonal tumors withmultilayeredrosettes(ETMR)

10.20 10.50 Poster Session and Coffee Break

10.50 12:10 Session V Chair: David Capper10.50 11.30 Plenary Lecture V Dolores Hambardzumyan (Altanta, USA) Subtypespecificdifferencesinmacrophage/microgliafunctioninglioblastoma

11.30 11.50 Oral Presentation IX Gregor Hutter (Basel, Switzerland) CD47-Sirpa blockade induces a microglial phenotypic shift and promotes active glioblastoma phagocytosis in vivo

11.50 12.10 Oral Presentation X Anna Gieryng (Warszawa, Poland) Minocyclinereducesproductionoftumor-derivedosteopontin/spp1andmodulatestheimmune microenvironment of rat c6 gliomas

12.10 13.10 Lunch (Cafeteria) and Postersession

13.00 15.30 Session VI Chair: Marcus Czabanka13.10 13.50 Plenary Lecture VI Brbara Melndez (Toledo, Spain) Molecular genetics in long-term survivors of glioblastoma

13.50 14.10 Oral Presentation XI Claudio Giachino (Basel, Switzerland) Opposite roles of notch signaling in the formation of distinct glioma subtypes

14.10 14.40 Poster Session and Coffee Break

14.40 15.20 Plenary Lecture VII Richard Gilbertson (Cambridge, UK) Mapping the origins and treatment of brain tumors

15.20 15.30 Awarding of Poster Prizes: Darko Markovic

15.30 Departure

7

Brain Tumor 2017

List of Plenary Lectures

Cameron W. BrennanNeurosurgery Department, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USAMolecularheterogeneityandinstabilityofdiffusegliomas:modelsandclinicalpractice

Richard GilbertsonDepartment of Oncology, Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UKMapping the origins and treatment of brain tumors

Dolores HambardzumyanEmory University School of Medicine, Department of Pediatrics, Atlanta GA 30322, USASubtypespecificdifferencesinmacrophage/microgliafunctioninglioblastoma

Eric Charles HollandUniversity of Washington, Fred Hutchinson Cancer Research Center, Seattle, USAGliomas: Big human data and mouse models

Brbara MelndezMolecular Pathology Research Unit, Virgen de la Salud Hospital, Toledo, SpainMolecular genetics in long-term survivors of glioblastoma

Colin WattsUniversity of Cambridge, John van Geest Centre for Brain Repair, Cambridge , UKSurgical strategies to interrogate the genomics of glioblastoma

Frank WinklerNeurology Clinic and National Center for Tumor Disease University Hospital Heidelberg, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, 69120 Heidelberg, GermanyNews from tumor microtubes in gliomas

Brain Tumor 2017

8

Abstracts of Plenary Lectures

MOLECULAR HETEROGENEITY AND INSTABILITY OF DIFFUSE GLIOMAS: MODELS AND CLINICAL PRACTICECameron BrennanNeurosurgery Department, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USAExtensive genomic and proteomic analyses of diffuse gliomas have revealed a remarkable degree of structure in their mutations and gene expression. For example, signature mutations in genes, including Tert, ATRX, TP53 and chromosomal arms 1p/19q clearly di-stinguish typical astrocytomas and oligodendrogliomas where these entities were previously defined by histopathology. Beyond these signature genes, the constellation of other mutations is also largely constrained to a palette of well-known common events: activating alterations of receptor tyrosine kinases and NF1, and alterations targeting tumor suppressor pathways. This presentation will sum-marize the relationship of common mutations and currently known omic signatures in diffuse gliomas, and investigate some of the mechanisms and ramifications of intratumoral heterogeneity in the responses of glioblastomas to conventional and targeted therapies.

MAPPING THE ORIGINS AND TREATMENT OF BRAIN TUMOURSRichard J. GilbertsonLi Ka Shing Chair of Oncology, Head of Dept. of Oncology, Director, Cambridge Cancer Center, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson Way Cambridge CB2 0RE, UKCancers are distributed unevenly across the body, but the impor-tance of cell intrinsic factors such as stem cell function in determi-ning organ cancer risk is unknown. Over the last 15 years we have developed the technique of cross-species genomics to map cells of origin of brain tumours in the developing nervous system. These studies have revealed that brain tumours arise from matched com-binations of susceptible cell types and oncogenic mutations. More recently we have built on these data to use Cre-recombination of conditional lineage tracing, oncogene, and tumour suppressor alleles to define populations of stem and non-stem cells in multiple mouse organs and test their life-long susceptibility to tumorigene-sis. We show that tumour incidence is determined by the life-long generative capacity of mutated cells. This rel